BUSINESS SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:

	2016		2015		2014
McKesson Corporation	22	%	21	%	20	%
AmerisourceBergen Corporation	18	%	16	%	17	%
Cardinal Health, Inc.	14	%	12	%	12	%

Selected geographic area information was as follows:

	Revenues						Property, Plant and Equipment
Dollars in Millions	2016		2015		2014		2016		2015
United States	$	10,720	$	8,188	$	7,716	$	3,865	$	3,681
Europe	4,215		3,491		3,592		1,003		616
Rest of the World(a)	3,964		4,142		3,459		112		115
Other(b)	528		739		1,112		—		—
Total	$	19,427	$	16,560	$	15,879	$	4,980	$	4,412

(a) Includes Japan which represented 7%, 10% and 6% of total revenues in 2016, 2015 and 2014, respectively.

(b) Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.

Product revenues were as follows:

	Year Ended December 31,
Dollars in Millions	2016		2015		2014
Oncology
Empliciti (elotuzumab)	$	150	$	3	$	—
Erbitux* (cetuximab)	—		501		723
Opdivo (nivolumab)	3,774		942		6
Sprycel (dasatinib)	1,824		1,620		1,493
Yervoy (ipilimumab)	1,053		1,126		1,308
Cardiovascular
Eliquis (apixaban)	3,343		1,860		774
Immunoscience
Orencia (abatacept)	2,265		1,885		1,652
Virology
Baraclude (entecavir)	1,192		1,312		1,441
Hepatitis C Franchise	1,578		1,603		256
Reyataz (atazanavir sulfate) Franchise	912		1,139		1,362
Sustiva (efavirenz) Franchise	1,065		1,252		1,444
Neuroscience
Abilify* (aripiprazole)	128		746		2,020
Mature Products and All Other	2,143		2,571		3,400
Total Revenues	$	19,427	$	16,560	$	15,879

The composition of total revenues was as follows:

	Year Ended December 31,
Dollars in Millions	2016		2015		2014
Net product sales	$	17,702	$	14,045	$	11,660
Alliance revenues	1,629		2,408		3,828
Other revenues	96		107		391
Total Revenues	$	19,427	$	16,560	$	15,879